- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07760311
Feasibility Study to Evaluate a Digital Tool for Monitoring Patients Who Have Discontinued Treatment for Chronic Myeloid Leukemia (FREE CML)
The objective of this project is to evaluate, over a 12-month period, the feasibility of integrating a digital tool into the follow-up care of patients with chronic myeloid leukemia who have been off treatment for up to 2 years. Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least:
- once a month, if treatment discontinuation was ≤ 6 months;
- once a quarter, if treatment discontinuation was > 6 months. The usage rate will be assessed and compared to a threshold of 60%; if the rate falls below this threshold, feasibility will be considered insufficient.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Laure Morisset
- Numéro de téléphone: +33139239785
- E-mail: lmorisset@ght78sud.fr
Lieux d'étude
-
-
-
Le Chesnay, France, 78150
- CH de Versailles
-
Contact:
- Laure MORISSET
- Numéro de téléphone: 0139239785
- E-mail: lmorisset@ght78sud.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients aged 18 or older
- Patients with chronic myeloid leukemia who have been off treatment for ≤ 2 years
- Patients with access to a digital device with internet access
- Be enrolled in the social security system
- Have given verbal consent after reviewing the study information sheet
Exclusion Criteria:
- Patients who cannot read or understand French;
- Individuals entitled to enhanced protection, namely minors, individuals deprived of their liberty by a judicial or administrative decision, individuals staying in a health or social care facility, adults under legal guardianship, and, finally, patients in emergency situations
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intervention arm
Integration of a digital tool into the follow-up care of patients with CML who have been off treatment for up to 2 years.
|
Integration of a digital tool into the follow-up care of patients with CML who have been off treatment for up to 2 years.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least: - once a month, if treatment interruption is ≤ 6 months; - once a quarter, if treatment interruption is > 6 months.
Délai: 12 months
|
To evaluate, over a 12-month period, the feasibility of integrating a digital tool into the care of patients with chronic myeloid leukemia
|
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of times patients used the device.
Délai: 12 months
|
Assess how often the device is used.
|
12 months
|
|
The number of days between when the blood test is performed and when the IPA and the patient view the results on the device.
Délai: 12 months
|
Assess the time it takes for the Study Nurse and the patient to access laboratory results.
|
12 months
|
|
The frequency with which patients contact the study nurse through the system's communication module.
Délai: 12 months
|
Evaluate the use of the digital device's data exchange module between the patient and the Study Nurse
|
12 months
|
|
Anxiety scores will be assessed at enrollment, at M3, M6, and M12 using the 7-item Generalized Anxiety Disorder Screening Scale (GAD-7) (scores range from 0 to 21).
Délai: 12 months
|
To study anxiety symptoms and their progression over the course of follow-up.
|
12 months
|
|
Changes in the GAD-7 anxiety score (0 to 21) based on the duration of treatment interruption (months) and the frequence
Délai: 12 months
|
To examine the relationship between changes in anxiety scores based on the duration of treatment interruption and the use of the device.
|
12 months
|
|
Patient satisfaction will be assessed using a questionnaire designed specifically for this population, consisting of 9 items (with a score ranging from 0 to 36) and a numerical scale for overall satisfaction ranging from 0 to 10.
Délai: 12 months
|
Assess patient satisfaction with the digital tool.
|
12 months
|
|
The tool's usability will be evaluated using the 10-item System Usability Scale (SUS) (0 to 100).
Délai: 12 months
|
Evaluate the usability of the digital device.
|
12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Cindy JAFFRY, Versailles Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- P25/02_FREE CML
- 2025-A02577-42 (Autre identifiant: ID-RCB Number)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .